Zilis Expands UltraCell Product Line with Launch of UltraCell Full Spectrum Hemp CBD Topical

ACCESSWIRE

Product Exclusively Available Through Zilis
Ambassadors

ARGYLE,
TX / ACCESSWIRE / October 11, 2018 /
Zilis LLC, the company leading the way in the burgeoning hemp-derived CBD industry with its ingestible liquid UltraCell product, has announced the latest innovation in its UltraCell
line: UltraCell Topical. Designed for topical application to help treat aches
and pains, the product debuted on Saturday, September 22nd in
Indianapolis at the company’s “Super Saturday” event for its independent
distributors (“Ambassadors”).

Reaction to the product was so strong on its debut date that Zilis sold nearly 20,000 jars of UltraCell Topical during the first 24 hours it was available.

Zilis Founder and CEO Steven Thompson commented: “Our Ambassadors asked, and we delivered, creating a full spectrum topical hemp CBD oil product with the superior bioavailability they have come to expect from UltraCell. We expect UltraCell Topical to continue to bring value to our customers, and to help our Ambassadors continue to change lives through this dynamic, breakthrough product.”

For centuries, the hemp plant, which is different from the marijuana plant, has been used for its medicinal benefits. CBD, or cannabidiol, is a compound found in both hemp and marijuana plants; a key difference between hemp-derived and marijuana-derived CBD is that hemp products, like UltraCell, contain only trace amounts of THC, the psychoactive component found in the marijuana plant.

Zilis, which launched in 2015, created UltraCell as an ingestible CBD oil in November 2017. Two hallmarks of the UltraCell brand since its launch are absorption and bioavailability; the Topical product delivers both of those benefits to customers. UltraCell full spectrum hemp oil has shown absorption at 94 percent (see study information below), and the bioavailability, made possible thanks to the water solubility of the UltraCell technology, is designed to be both fast acting and long lasting.

Dr. Derrick DeSilva, Jr., M.D., Chief Medical Officer of Zilis, said: “The medical community is just beginning to catch up with the possibilities contained in the hemp plant, and the UltraCell Topical is helping to open the eyes of the health care world. Combining our market-leading absorption with superior bioavailability creates a powerful combination that, together with the other ‘entourage’ components of UltraCell Topical, can potentially help with a variety of ailments.”

In addition to the full spectrum hemp oil found in UltraCell Topical, the product provides a number of other beneficial extracts as part of its entourage. These components, part of the proprietary UltraCell blend, work with the CBD oil to maximize its effect. These extracts include:

  • Black pepper oil, which has been shown to provide relief from cramps and spasms;
  • Citronella oil, used to help fight free radical damage in cells;
  • Helichrysum oil, which can help treat inflammation; and
  • Ginger root oil, which has been used to treat muscle aches, joint discomfort, and migraines.

Available only through a Zilis Ambassador, UltraCell Topical is sold in a two-ounce jar, with a suggested retail price of $149.

As a direct sales company, Zilis trusts its network of independent ambassadors to sell its product to consumers. Ambassadors are joining the Zilis ranks at breakneck speed, with thousands joining since September 1, 2018.

About Zilis LLC

Zilis®, is the creator of UltraCell®, a CBD oil product derived from hemp. With independent direct sales ambassadors throughout the country, Zilis has been at the forefront of the movement to harness the power of hemp, and specifically its CBD oil, which is used by tens of thousands throughout the world as a dietary supplement. Based in Argyle, Texas, a suburb of Dallas-Fort Worth, Zilis is privately held. Zilis and its ambassadors are committed to giving back as “The Pay It Forward Company™,” and the company has donated tens of millions of days’ worth of vitamin supplements to the developing world during 2018. Visit https://zilis.com for more information.

Product
Disclaimer

Zilis products have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease or medical conditions. The information on the Zilis website, marketing materials, product labels or packaging is not intended as medical advice and should not substitute advice from a healthcare professional. Please consult with your physician or other healthcare provider if you have health-related questions before using any of our products or relying on any information you obtain from the Zilis website. You should discuss any medications or nutritional supplements you are using with a healthcare provider before using any new medications or supplements. Always review the labels, warnings, and directions included with your product before using or consuming the product and do not rely solely on the information shown on the Zilis website.

For More
Information, Contact:

Dave Van de Walle
(940) 535-7200, ext. 219
dave[email protected]

SOURCE: Zilis LLC

https://www.accesswire.com/viewarticle.aspx?id=513944

Leave a Reply